1. The Role of Government and Private Insurers in Guiding and Implementing Pharmacoeconomic Analyses

   • Deborah A. Freund
   • Bryan R. Luce

   Current Opinion 18 October 2012 Pages: 383 - 387

2. The (Near) Equivalence of Cost—Effectiveness and Cost-Benefit Analyses

   • Cam Donaldson

   Current Opinion 18 October 2012 Pages: 389 - 396

3. An Introduction to Markov Modelling for Economic Evaluation

   • Andrew Briggs
   • Mark Sculpher

   Leading Article 18 October 2012 Pages: 397 - 409

4. The Use of QALY and Non—QALY Measures of Health—Related Quality of Life

   • Mark Deverill
   • John Brazier
   • Andrew Booth

   Review Article 18 October 2012 Pages: 411 - 420

5. Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample

   • Jeffrey A. Johnson
   • Stephen Joel Coons
   • George Szava-Kovats

   Original Research Article 18 October 2012 Pages: 421 - 433

6. Antidepressant Selection and Use and Healthcare Expenditures

   • William H. Crown
   • Timothy R. Hylan
   • Laurie Meneades

   Original Research Article 18 October 2012 Pages: 435 - 448

7. Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus

   • Kurt Banz
   • Rolf Dinkel
   • Uta Schwanebeck

   Original Research Article 18 October 2012 Pages: 449 - 459

8. Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with AIDS

   • Robert I. Griffiths
   • Giselle C. Bleecker
   • Earl P. Steinberg

   Original Research Article 18 October 2012 Pages: 461 - 474